Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash

cnbc.com/2025/10/26/novartis-avidity-biosciences-talks.html

Swiss pharmaceutical giant Novartis has agreed to buy biotechnology company Avidity Biosciences for about $12 billion, the company said Sunday.
Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company's Friday closing price.
The deal is expected to…

This story appeared on cnbc.com, 2025-10-26 20:18:18.786000.
The Entire Business World on a Single Page. Free to Use →